These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3304952)

  • 1. The effect of cyclandelate on cholesterol metabolism in patients with familial hypercholesterolaemia.
    Gevers Leuven JA; vd Voort H; Kempen HJ; de Wit E; Havekes L
    Drugs; 1987; 33 Suppl 2():131-5. PubMed ID: 3304952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
    Wiklund O; Angelin B; Fager G; Eriksson M; Olofsson SO; Berglund L; Lindén T; Sjöberg A; Bondjers G
    J Intern Med; 1990 Sep; 228(3):241-7. PubMed ID: 2119417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
    Betteridge DJ; Bhatnager D; Bing RF; Durrington PN; Evans GR; Flax H; Jay RH; Lewis-Barned N; Mann J; Matthews DR
    BMJ; 1992 May; 304(6838):1335-8. PubMed ID: 1611329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.
    Nappi G; Sandrini G; Savoini G; Cavallini A; de Rysky C; Micieli G
    Drugs; 1987; 33 Suppl 2():103-9. PubMed ID: 3304950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
    Jones DB; Simpson HC; Slaughter P; Lousley S; Carter RD; Cobbe SM; Mann JI
    Atherosclerosis; 1984 Oct; 53(1):1-7. PubMed ID: 6388586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia.
    Curtis LD; Dickson AC; Ling KL; Betteridge J
    BMJ; 1988 Jul; 297(6642):173-5. PubMed ID: 3044508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
    Hoeg JM; Maher MB; Bailey KR; Zech LA; Gregg RE; Sprecher DL; Brewer HB
    Am J Cardiol; 1985 May; 55(11):1282-6. PubMed ID: 3887883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated charcoal in the treatment of hypercholesterolaemia: dose-response relationships and comparison with cholestyramine.
    Neuvonen PJ; Kuusisto P; Vapaatalo H; Manninen V
    Eur J Clin Pharmacol; 1989; 37(3):225-30. PubMed ID: 2612535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition.
    Angelin B; Eriksson M; Einarsson K
    Eur J Clin Invest; 1986 Oct; 16(5):391-6. PubMed ID: 3100307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
    Mol MJ; Stuyt PM; Demacker PN; Stalenhoef AF
    Neth J Med; 1990 Apr; 36(3-4):182-90. PubMed ID: 2355995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypolipidemic effect and mechanism of ketoconazole without and with cholestyramine in familial hypercholesterolemia.
    Gylling H; Vanhanen H; Miettinen TA
    Metabolism; 1991 Jan; 40(1):35-41. PubMed ID: 1984567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.
    Durrington PN; Miller JP
    Atherosclerosis; 1985 May; 55(2):187-94. PubMed ID: 3890872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia.
    Albizzati MG; Bassi S; Calloni E; Sbacchi M; Piolti R; Frattola L
    Drugs; 1987; 33 Suppl 2():90-6. PubMed ID: 3304956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with cyclandelate in insulin-dependent diabetic patients with neuropathy.
    De Leeuw IH; Van Rooy P; Moeremans M; Driessens M
    Drugs; 1987; 33 Suppl 2():125-30. PubMed ID: 3304951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with simvastatin compared with cholestyramine.
    Erkelens DW; Baggen MG; Van Doormaal JJ; Kettner M; Koningsberger JC; Mol MJ
    Drugs; 1988; 36 Suppl 3():87-92. PubMed ID: 3254824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of probucol and cholestyramine combination therapy in severe familial hypercholesterolaemia.
    Jackson JM; Lee HA
    Atherosclerosis; 1984; 51(2-3):189-97. PubMed ID: 6743378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclandelate on dementia.
    Westreich G; Alter M; Lundgren S
    Stroke; 1975; 6(5):535-8. PubMed ID: 1101457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined drug therapy for familial hypercholesterolemia.
    Packard CJ; Stewart JM; Morgan HG; Lorimer AR; Shepherd J
    Artery; 1980; 7(4):281-9. PubMed ID: 7213018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.